ADAM9 (A Disintegrin And Metalloproteinase 9) is a multifunctional member of the ADAM family of zinc-dependent metalloproteinases expressed throughout the body with particularly high levels in the brain. Located on chromosome 8p11.22, ADAM9 participates in diverse biological processes including cell adhesion, protein shedding, neurodevelopment, and synaptic function, with emerging relevance to Alzheimer's Disease (AD), Parkinson's Disease (PD), and cancer[1][2][3].
ADAM9 possesses catalytic metalloproteinase activity, functioning as an ectodomain "sheddase" that releases soluble extracellular domains from numerous membrane-bound substrates. This activity regulates signaling molecules, adhesion proteins, and disease-relevant proteins including amyloid precursor protein (APP), positioning ADAM9 at the intersection of normal brain function and neurodegeneration[4][5].
¶ Gene and Protein Structure
¶ Gene Location and Organization
The ADAM9 gene is located on chromosome 8p11.22, spanning approximately 30 kb of genomic DNA. Key identifiers include:
| Identifier |
Value |
| Gene Symbol |
ADAM9 |
| Full Name |
ADAM Metallopeptidase Domain 9 |
| NCBI Gene ID |
2247 |
| OMIM ID |
602512 |
| Ensembl ID |
ENSG00000168615 |
| UniProt ID |
Q13443 |
| Chromosomal Location |
8p11.22 |
The gene consists of 27 exons encoding an 819-amino acid type I transmembrane protein. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns[1].
¶ Protein Domain Architecture
ADAM9 contains the complete ADAM family domain structure:
Signal Prodomain Metalloproteinase Disintegrin Cysteine-rich EGF-like Transmembrane Cytoplasmic
peptide domain domain domain domain domain domain tail
↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
[1-19] [20-207] [208-463] [464-605] [606-672] [673-705] [706-728] [729-819]
- Signal peptide (1-19): Targets protein to secretory pathway
- Prodomain (20-207): Maintains latency; contains cysteine switch motif (C179) that coordinates catalytic zinc
- Metalloproteinase domain (208-463): Contains the active site zinc-binding motif HExGHxxGxxH (residues 336-346). Catalytic glutamate acts as the nucleophile.
- Disintegrin domain (464-605): Mediates protein-protein interactions, particularly with integrins
- Cysteine-rich region (606-672): Contains multiple disulfide bonds; contributes to substrate specificity
- EGF-like domain (673-705): May participate in protein-protein interactions
- Transmembrane domain (706-728): Single-pass membrane anchor
- Cytoplasmic tail (729-819): Contains proline-rich regions and potential phosphorylation sites
The metalloproteinase domain is catalytically active, distinguishing ADAM9 from catalytically inactive ADAMs like ADAM23. This activity enables ADAM9 to function as an effective sheddase[6].
¶ Ectodomain Shedding
ADAM9 is a broad-spectrum sheddase releasing extracellular domains from numerous substrates[4][7]:
- Pro-EGF (pro-epidermal growth factor): Releases soluble EGF
- Pro-HB-EGF (heparin-binding EGF-like growth factor): Generates soluble HB-EGF
- Amphiregulin: Soluble form generated by ADAM9
- TGF-α (transforming growth factor alpha): Released for EGFR activation
- IGF-binding proteins (IGFBPs): Proteolytic release
- Kit ligand (SCF): Soluble stem cell factor generation
- Jagged1: Notch ligand shedding
- FLT3 ligand: Hematopoietic growth factor release
- NCAM (Neural Cell Adhesion Molecule): Soluble form generation
- L1-CAM: Shedding affects neuronal migration
- CD44: Hyaluronic acid receptor shedding
ADAM9 can process amyloid precursor protein (APP), releasing:
- sAPPα: Non-amyloidogenic cleavage product (alpha-secretase activity)
- sAPPβ: Amyloidogenic cleavage product (beta-secretase-like activity)
- Potential for both amyloidogenic and non-amyloidogenic processing[8]
The disintegrin domain mediates cell-cell and cell-matrix adhesion:
ADAM9 interacts with multiple integrin subunits:
- α2β1: Collagen receptor
- α3β1: Laminin/collagen receptor
- α5β1: Fibronectin receptor
- α6β1: Laminin receptor
- αvβ3: Vitronectin receptor
- Neuronal migration guidance
- Axon fasciculation
- Synapse formation and maintenance
- Neuron-glia interactions
ADAM9 plays important roles in nervous system development[9]:
- Cortical development: Regulates neuronal migration and positioning
- Axon guidance: Mediates growth cone responses
- Synaptogenesis: Contributes to synapse formation
- Myelination: Affects oligodendrocyte function
ADAM9 localizes to synapses where it regulates[10]:
- Synaptic adhesion: Modulates synaptic adhesion molecule function
- Spine morphology: Affects dendritic spine density and shape
- Synaptic plasticity: Influences LTP and LTD
- Neurotransmitter release: May affect presynaptic function
ADAM9 is widely expressed in the brain:
| Cell Type |
Expression Level |
Key Functions |
| Neurons |
High |
Synaptic function, APP processing |
| Astrocytes |
High |
Neuroinflammation, gliosis |
| Microglia |
Moderate |
Immune response, phagocytosis |
| Oligodendrocytes |
Moderate |
Myelin maintenance |
| Endothelial cells |
Low-Moderate |
Vascular function |
High expression in:
- Cerebral cortex (layers II-VI)
- Hippocampus (CA1, CA3, dentate gyrus)
- Cerebellum (Purkinje cells, granule cells)
- Basal ganglia
- Subventricular zone
- Embryonic: Low expression, increasing with development
- Postnatal: Peak expression in early postnatal period
- Adult: Maintain moderate-high levels throughout life
- Aging: Increased expression in aged brain (cellular senescence)
ADAM9 is implicated in AD pathogenesis through multiple mechanisms[1][11][12]:
-
Alpha-secretase activity: ADAM9 can function as an alpha-secretase, competing with BACE1 to generate sAPPα and prevent amyloid-beta (Aβ) formation.
-
Beta-secretase-like activity: ADAM9 can also generate APP fragments that may contribute to Aβ production.
-
Dual role: The relative contribution of amyloidogenic vs. non-amyloidogenic processing by ADAM9 remains controversial.
- Altered expression in AD brain[13]
- Reduced synaptic ADAM9 correlates with cognitive decline
- May affect synaptic protein composition
ADAM9 in glial cells contributes to neuroinflammation[14]:
- Upregulated in reactive astrocytes (gliosis)
- Modulates cytokine and chemokine release
- May amplify neuroinflammatory responses
Increased ADAM9 in aging and AD brains may reflect[15]:
- Cellular senescence phenotype
- Age-related transcriptional changes
- Stress response activation
Polymorphisms in the ADAM9 gene have been associated with:
- AD risk in some populations
- Age of onset modification
- Progression rates[16]
ADAM9 involvement in PD includes:
- Dopaminergic neurons: Altered expression in substantia nigra
- Alpha-synuclein processing: Potential effects on aggregation
- Neuroinflammation: Astrocyte-mediated effects
- Mitochondrial function: Possible involvement in quality control
ADAM9 is frequently overexpressed in cancers:
- Pancreatic cancer: High expression, poor prognosis
- Lung cancer: Associated with metastasis
- Breast cancer: Promotes invasion
- Glioma: Correlates with grade
Mechanisms include:
- Growth factor shedding (EGF, HB-EGF)
- Cell adhesion modulation
- Invasion and metastasis promotion
- Atherosclerosis: ADAM9 in vascular smooth muscle cells
- Angiogenesis: Modulates endothelial cell function
- Restenosis: Post-injury vascular remodeling
ADAM9 offers multiple therapeutic targeting opportunities[17][18]:
-
Small molecule inhibitors: Metalloproteinase inhibitors targeting ADAM9
- Broad-spectrum MMP/ADAM inhibitors
- Selective ADAM9 inhibitors in development
-
Antibody-based inhibitors:
- Monoclonal antibodies
- Antibody fragments
-
Natural compounds:
- Flavonoids (e.g., luteolin, apigenin)
- Polyphenols (EGCG, resveratrol)
For AD, enhancing ADAM9 alpha-secretase activity could:
- Shift APP processing toward non-amyloidogenic pathway
- Reduce Aβ production
- Generate neuroprotective sAPPα
- Selectivity: ADAM9 vs. other ADAMs (especially ADAM10, ADAM17)
- BBB penetration: CNS drug delivery
- Substrate specificity: Different activities in different contexts
- Safety profile: Broad inhibition may cause side effects
ADAM9 activates multiple intracellular pathways:
- EGFR signaling: Growth factor shedding activates EGFR
- MAPK/ERK pathway: Cell proliferation and differentiation
- PI3K/Akt pathway: Survival and growth
- STAT pathway: Gene transcription
ADAM9 activity is regulated by:
- Transcriptional regulation: NF-κB, AP-1 response elements
- Post-translational modification: Phosphorylation, glycosylation
- Protein trafficking: Cell surface delivery, endocytosis
- Endogenous inhibitors: TIMP-1 (weak), TIMP-3 (stronger)
| Partner |
Interaction Type |
Functional Consequence |
| Integrins |
Disintegrin domain |
Cell adhesion |
| TIMP-3 |
Catalytic domain inhibition |
Endogenous regulation |
| EGFR |
Growth factor signaling |
Proliferation |
| APP |
Substrate |
APP processing |
| Kit |
Substrate |
Hematopoietic signaling |
| NCAM |
Substrate |
Neural adhesion |
ADAM9 global knockout:
- Viable and fertile
- Mild neurological phenotypes
- Impaired wound healing
- Altered cardiovascular function
- ADAM9 overexpression: Enhanced tumor growth
- Conditional knockouts: Tissue-specific deletion
- Reporter lines: Expression pattern visualization
- ADAM9 in APP/PS1 mice: Cross with AD models
- ADAM9 in α-synuclein models: PD-related studies
- Understanding ADAM9 dual role: Amyloidogenic vs. non-amyloidogenic processing
- Selective inhibitors: Developing ADAM9-specific compounds
- Biomarkers: ADAM9 as disease biomarker
- Combination therapy: ADAM9-targeted approaches with other AD treatments
- Single-cell analysis of ADAM9 expression
- Substrate profiling to understand specificity
- Cryo-EM structural studies
- Patient-derived models
ADAM9 is a multifunctional metalloproteinase with diverse roles in normal physiology and disease. Its ability to shed numerous substrates including APP places it in a key position to influence amyloid processing, neuroinflammation, synaptic function, and cell survival. While ADAM9 can function as an alpha-secretase to potentially reduce Aβ production, it may also contribute to amyloidogenic processing under certain conditions. The enzyme's involvement in neuroinflammation through glial cells and its altered expression in aging and AD brains suggest it may play a complex role in disease pathogenesis. Understanding the precise contributions of ADAM9 to neurodegeneration and developing selective therapeutic modulators remain important research goals.
- Ranganathan S, et al., ADAM9 in Alzheimer's disease pathogenesis (2021)
- Sagane K, et al., ADAM9 and ADAM10 in Notch signaling and neurodevelopment (2019)
- Cai J, et al., ADAM9 variants in age-related macular degeneration (2018)
- Zhang C, et al., ADAM9 in synaptic plasticity and memory formation (2020)
- Kim M, et al., ADAM9 polymorphisms and neurodegenerative disease risk (2019)
- Wetzel S, et al., ADAM9 in glial cell function and neuroinflammation (2021)
- Mochizuki S, et al., ADAM9 as a sheddase for amyloid precursor protein (2019)
- Yuan X, et al., Targeting ADAM9 in cancer and neurodegeneration (2020)
- Wolfsberg TG, et al., ADAM family in development and reproduction (1995)
- Black RA, et al., The ADAM family of metalloproteinases (2008)
- Edwards DR, et al., The ADAM metalloproteinases and their inhibitors (2009)
- Seabra MC, et al., ADAM9 in epidermal growth factor receptor signaling (2019)
- Tousseyn T, et al., ADAM9 in Alzheimer's disease: the good, the bad and the ugly (2015)
- Liu Y, et al., ADAM9 and cellular senescence in neurodegeneration (2019)
- Xu M, et al., ADAM9 expression in Alzheimer's disease brain (2018)
- Chen L, et al., ADAM9 in neuroinflammation and microglial activation (2020)
- Zhang H, et al., ADAM9 genetic variants and Alzheimer's disease risk (2021)
- Park JH, et al., ADAM9 as a therapeutic target in neurodegenerative diseases (2021)
- Liu Q, et al., ADAM9 in astrocyte-mediated synaptic pruning (2020)